Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.53 |
| ▸ | NPY1R | P25929 | 10/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.53 |
| ▸ | NPY2R | P49146 | 6/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.48 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.47 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30495709 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL30111249 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RTFPI | |
| SCHEMBL29993069 | 0.94 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL13107806 | 0.94 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL30509261 | 0.94 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL31019151 | 0.94 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL2790810 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29794248 | 0.92 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RQRFPR | |
| SCHEMBL2790809 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29590942 | 0.91 | QRFPR (0.52) | NPY4RNPY1RNPY5RNPY2RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | NPY4R 4433/4885NPY1R 3079/4885NPY5R 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.